Sean W. Pawlowski, M.D.

Office: 950 E Harvard, Ste 140

Denver, CO 80210 w-(303)777-0781

sean.pawlowski@coloradoid.com

Emi	ala	m	ont
	יטוט	viii	eni

Employment Medical Director of Antimicrobial Stewardship and Infection Control, Swedish Medical Center, Englewood, CO	10/2014-present
Medical Director of Antimicrobial Stewardship, Porter Adventist Hospital, Denver, CO	07/2013-08/2020
Medical Director of Infection Control, Porter Adventist Hospital, Denver, CO	07/2013-08/2015
Antimicrobial Stewardship and IC Consultant Orchard Park Healthcare Facility, Denver, CO	07/2013-present
Colorado Infectious Disease Associates LLP, Partner, Denver, CO	08/2010-present
Education Fellowship-Infectious Diseases, University of Virginia School of Medicine, Charlottesville, VA	2007-2010
Internship/Residency-Internal Medicine, University of Colorado Health Science Center, Denver, CO	2004-2007
M.D University of Texas Health Science Center, Houston, TX	2000-2004
B.ABiology, University of Texas, Austin, TX	1992-1996
Appointments/Committees Medical Director of Antimicrobial Stewardship and Infection Control, Swedish Medical Center, Englewood, CO	10/2014-present
Medical Director of Antimicrobial Stewardship, Porter Adventist Hospital, Denver, CO	04/2013-08/2020
Medical Director of Infection Control, Porter Adventist Hospital, Denver, CO	07/2013-08/2015
Clinical Instructor/Clinical Faculty, University of Colorado, Denver, CO	01/2012-present
BMC Infectious Diseases journal- Invited reviewer	2012
Board Certification and Licensure American Board of Internal Medicine-Infectious Diseases-Board Certified	10/2010, 05/2021
Colorado Medical License	04/2010
Professional Memberships and Activities HIV Medicine Association	
Infectious Disease Society of America	2011-present
American Medical Association	2007-present
	2000-2010
Honors and Awards Gerald L Mandell Most Outstanding ID Research Fellow-UVA	06/2010
Merle A Sande Most Outstanding ID Clinical Fellow-UVA	06/2010
Most outstanding presentation by a Fellow/PhD candidate. Carey, Marshall, Thorner Scholars Research Day. UVA.	05/2008

Invited Presentations

Infections in Long Term Care. For Summit Medical Consultants. Jun 2023.

Clostridioides (don't call me Clostridium) difficile update. HCA Internal Medicine Grand Rounds. Jun 2023

Updates on the use of Remdesivir and Convalescent serum in COVID19. Swedish Medical Center. Apr 2020

Antimicrobial Stewardship in Rehab and LTC. South Denver Care Continuum. Denver, CO. May 2019

C.difficile: The Case for Stool Transplant. Porter Critical Care Nurses Council. Porter Hospital. Denver, CO. April 2016.

Fevers and Lymphadenopathy in a patient with CLL. Infectious Diseases Pathogenesis Case Conference. Swedish Medical Center. Englewood, CO. Feb 2016.

Defining CA-UTI: Where knowing is more than half the battle. Swedish Medical Center Grand Rounds. Englewood, CO. July 2015.

Antimicrobial Stewardship: Where less use really is more. Swedish Medical Center Grand Rounds. Englewood, CO. Oct. 2014

Clostridium difficle update: the end of metronidazole, FMT, and other revelations. Association for Professionals in Infection Control and Epidemiology: Rocky Mountain Chapter Meeting. Denver, CO. Sep. 2014.

Clostridium difficile update: The end of metronidazole and other revelations. Denver Intercity ID Rounds. Sep. 2014.

Update on *C.difficile*. Swedish Medical Center Grand Rounds. Englewood, CO. March 2014.

Infection Control 101-Infection Control in the Long Term Care Setting. Orchard Park Healthcare Center. Denver, CO. Oct 2013

Antimicrobial Stewardship: A Story of Bacterial Resistance and Economics. Craig Hospital Annual Physician Meeting. Englewood, CO. April 2013

A Case of Adrenal Histoplasmosis, Mar 2012, A Case of *Plasmodium vivax* June 2012, A case of Aspergillus Jan 2013, A case of cutaneous Mucormycosis May 2013. A case of Kaposis Sarcoma May 2014. A case of osteoarticular tuberculosis. Infectious Diseases Pathogenesis Case Conference. Swedish Medical Center, Englewood CO.

C.difficile case discussion, Swedish Hospital Program Improvement/Quality Improvement small group sessions. Englewood, CO. Sept 2012

C.difficile: Calling all stool donors. AVISTA Grand Rounds. Louisville, CO March 2012.

C.difficile: What's new and what to do? Association for Professionals in Infection Control and Epidemiology: Rocky Mountain Chapter Meeting. Denver, CO. February 2012.

C.difficile: Calling all stool donors. Swedish Medical Center Grand Rounds. Englewood, CO February 2012.

Empiric antibiotic coverage in health care associated sepsis. Swedish Hospital Critical Care Grand Rounds. Englewood, CO. January 2012.

Recurrent *Clostridium difficile*: calling all stool donors. Colorado Infection Prevention Collaborative. Denver, CO. June 2011.

Unraveling the C.difficile epidemic. Swedish Medical Center Critical Care Grand Rounds. Englewood, CO. Febuary 2011.

C.difficile: More than "Just diarrhea." Craig Hospital Grand Rounds. Denver, CO. December 2010.

Abstracts/Posters

Anderson H, Mueller K, **Pawlowski SW**. Utilization of a pharmacist-driven penicillin allergy protocol to reduce use of unnecessary broad spectrum antibiotics. ASHP Midyear meeting. Resident Poster Presentation. Dec 2015.

Jenkins T, Caldwell B, Mccollister B, Moore S.J., O'leary S, **Pawlowski S**, Perlman D, Saveli C, Knepper B, Burman W Comparison of the microbiology and antibiotic treatment between diabetic and non-diabetic patients hospitalized with acute bacterial skin and skin structure infection. IDSA Oct 2014.

Jenkins T, Caldwell B, Mccollister B, Moore S.J., O'leary S, **Pawlowski S**, Perlman D, Saveli C, Knepper B, Burman W Microbiology and antibiotic treatment among injection drug users and non injection drug users hospitalized with acute bacterial skin and skin structure infection. IDSA Oct 2014.

Pawlowski SW, Lozano R, Roberts K. *Clostridium difficile* infection presentation and recurrence risks in spinal cord and traumatic brain injury patients in an inpatient rehabilitation hospital. IDSA 2103. Poster presentation

Jenkins T, Caldwell B, Mccollister B, Moore S.J., O'leary S, **Pawlowski S**, Perlman D, Saveli C, Knepper B, Burman W. Antibiotic Prescribing Practices and Factors Affecting Prescribing in Patients Hospitalized with Acute Bacterial Skin and Skin Structure Infection: Results of a Multi-Center Study. IDSA 2013-Poster presentation

Moore S.J, O'Leary S, Caldwell B, **Pawlowski SW**, Burman W, Jenkins T. Antibiotic Prescribing in Pediatric Patients Hospitalized with Acute Bacterial Skin and Skin Structure Infection. IDSA 2013-Poster presentation

Pawlowski SW, Kolling GL, Calabrese et al. Aging predisposes mice to acute symptomatic disease and prolonged weight loss in a murine model of *Clostridium difficile* infection. IDSA 2011. Poster presentation.

Pawlowski SW, Kolling GL, Calabrese G, et al. Aging predisposes mice to acute symptomatic disease and prolonged weight loss in a murine model of *Clostridium difficile* infection. UVA Department of Medicine Research Day 2010. Poster presentation.

Pawlowski SW, Calabrese G, Kolling GL, et al. A novel murine model of *Clostridium difficile* infection using clindamycin exposed or germ-free aged mice. UVA Department of Medicine Research Day 2009. Poster presentation.

Pawlowski SW, Calabrese G, Kolling GL, et al. A novel murine model of *Clostridium difficile* infection using clindamycin exposed or germ-free aged mice. IDSA 2009. Oral Presentation.

Pawlowski SW, Sevilleja JE, Kolling GL, et al. Factors other than bacterial or toxin concentrations likely contribute to intestinal inflammation in *Clostridium difficile* infection. ICAAC-IDSA 2008, B-3801. Poster presentation.

Pawlowski SW, AlcantaraWarren C, Linden J, et al. Enhanced anti-inflammatory and anti-secretory effect of an A_{2a} adenosine receptor agonist with co-administration of alanyl-glutamine in the rabbit model of *Clostridium difficile* ileitis. ICAAC-IDSA 2008, B-3800. Poster presentation.

Pawlowski SW, Archbald-Pannone L, Carman RJ, et al. *Clostridium difficile*: the role of fluoroquinolone resistance. UVA Infectious Diseases Research in Progress 2008. Oral presentation.

Pawlowski SW, AlcantaraWarren C, Linden J, et al. Enhanced anti-inflammatory and anti-secretory effect of an A_{2a} adenosine receptor agonist with co-administration of alanyl-glutamine in the rabbit model of *Clostridium difficile* ileitis. UVA Department of Medicine Research Day 2008. Poster presentation.

Pawlowski SW, Archbald-Pannone L, Carman RJ, et al. Fluoroquinolone resistance correlates with *Clostridium difficile* intestinal inflammation, independent of the tcdC deletion, binary toxin genes, and REA type. UVA Carey, Marshall, Thorner Scholars Research Day 2008. Oral presentation.

Pawlowski SW, Archbald-Pannone L, Carman RJ, et al. Fluoroquinolone resistance, independent of binary toxin genes and tcdC deletion, is associated with inflammation in *Clostridium difficile* associated diarrhea (CDAD). UVA Infectious Diseases Research Day 2007. Oral presentation.

Publications

Journal Manuscripts

Shin JH, **Pawlowski SW**, Warren CA. Teaching old mice new tricks: the utility of aged mouse models of *C. difficile* infection to study pathogenesis and rejuvenate immune response. Gut Microbes. 2021 Jan-Dec;(13):1

Jenkins TC, Knepper BC, McCollister BD, Moore SJ, **Pawlowski SW**, Perlman DM, Saveli CC, O'Leary ST, Burman WJ. Failure of outpatient antibiotics among patients hospitalized for acute bacterial skin infections: What is the clinical relevance? Am J Emerg Med. 2016 Jun;34(6):957-62

Jenkins T, Caldwell B, Mccollister B, Moore S.J., O'leary S, **Pawlowski S**, Perlman D, Saveli C, Knepper B, Burman W Microbiology and antibiotic treatment among injection drug users and non injection drug users hospitalized with acute bacterial skin and skin structure infection. Acad Emerg Med. 2015 Aug;22(8):993-7.

Jenkins T, Caldwell B, Mccollister B, Moore S.J., O'leary S, **Pawlowski S**, Perlman D, Saveli C, Knepper B, Burman W Comparison of the microbiology and antibiotic treatment among diabetic and non-diabetic patients hospitalized for cellulitis or cutaneous abscess. Journ of Hosp Med 2014 Dec;9(12):788-94.

Pawlowski SW. Clostridium difficile infection update for the hospital-based physician. Curr Emer and Hosp Med Reports. 2014. DOI:10.1007/s40138-014-0053-7

Moore SJ, O'Leary ST, Caldwell B, Knepper BC, **Pawlowski SW**, Burman WJ, Jenkins TC. Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection. Ped Infect Dis J 2014; 33:825-28.

Jenkins TC, Knepper BC, Moore SJ, O'Leary ST, Caldwell B, Saveli CC, **Pawlowski SW**, Perlman DM, McCollister BD, Burman WJ. Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection. Infect Control Hosp Epidemiol. 2014 Oct;35(10):1241-1250.

Bonatti H, Metzger R, Swenson B, **Pawlowski S**, et al. Solid organ recipients are at increased risk for recurrent Clostridium difficile colitis. European Surgery. 2014 Aug 46(4): 160-164.

Warren CA, Calabrese GM, Li Y, **Pawlowski SW**, et al. Effects of of adenosine A2A receptor activation and alanyl-glutamine in *Clostridium difficile* toxin-induced ileitis in rabbits and cecitis in mice. BMC Infectious Diseases. 2012 Jan 20.12:13.

Pawlowski SW, Allen CA, Sevilleja JE, et al. Persistent nausea, vomiting, and diarrhea in an immunocompetent elderly gentleman. Clin Infect Dis. 2011 Feb 15:52:551-552.

Pawlowski SW, Calabrese G, Kolling GL, et al. Murine model of *Clostridium difficile* infection (CDI) using aged germ-free C57BL/6 mice and a BI strain. J Infect Dis.2010 Dec 1;202(11):1708-12.

Pawlowski SW, Moore CC, Wispelwey B. Persistent hiccups due to fixed-dose tenofovir and emtricitabine: A case report and review of hiccups in patients with HIV. Infectious Disease in Clinical Practice. Epub 21 Sept 2010.

Pawlowski SW, Archbald-Pannone L, Carman RJ, et al. Elevated levels of intestinal inflammation in *Clostridium difficile* infection (CDI) associated with fluoroquinolone resistant *C. difficile*. J Hosp Infect. 2009 Oct:73(2):185-7.

Pawlowski SW, AlcantaraWarren C, Guerrant RL. Diagnosis and treatment of acute and persistent diarrhea. Gastroenterology 2009 May;136(6):1874-86.

Books/Chapters

Pawlowski SW. Evaluation of Acute Diarrhea. In: BMJ Point of Care. 2012-2021

Pawlowski SW, Scheld WM. *Cryptococcus neoformans* meningoencephalitis. In: Caplivski D, Scheld WM. Consultations in Infectious Diseases: A case based approach to diagnosis and management. Oxford Press. 2012

Pawlowski SW, Scheld WM. HSV meningitis. In: Caplivski D, Scheld WM. Consultations in Infectious Disease: A case based approach to diagnosis and management. Oxford Press. 2012.

Pawlowski SW, Scheld WM. *Streptococcus intermedius* brain abscess. In: Caplivski D, Scheld WM. Consultations in Infectious Diseases: A case based approach to diagnosis and management. Oxford Press. 2012.

Pawlowski SW, Scheld WM. Cutaneous *Alternaria*. In: Caplivski D, Scheld WM. Consultations in Infectious Diseases: A case based approach to diagnosis and management. Oxford Press. 2012.

Pawlowski SW, Scheld WM. *Mycobacteria tuberculosis* osteomyelitis. In: Caplivski D, Scheld WM. Consultations in Infectious Diseases: A case based approach to diagnosis and management. Oxford Press. 2012.

Pawlowski SW, Scheld WM *Plasmodium vivax*. In: Caplivski D, Scheld WM. Consultations in Infectious Diseases: A case based approach to diagnosis and management. Oxford Press. 2012.

Pawlowski SW, Guerrant RL. Perspective: The Global Burden of Diarrheal Disease. In: Centers for Disease Control and Prevention. CDC Health Information for International Travel 2010. Atlanta: US Department of Health and Human Services, Public Health Service. 2009.

Additional Projects/Ongoing Studies

INSPIRE ABD/SST Infection Trial. Swedish Hospital. Physician Stewardship Team. Swedish Medical Center. Englewood, CO. 2022

GS-US-540-5821: Expanded Access Treatment Protocol: Remdesivir (RDV) for the Treatment of SARS-CoV2 Infection. Study Site Clinical Investigator. Swedish Medical Center. Englewood, CO. 05/2020

Utilization of pharmacists to evaluate and challenge "penicillin" allergic patients to help reduce the use of non-penicillin antibiotics. Swedish Medical Center, Englewood, CO. 2015-2017

Committee member to obtain approval and perform Stool Transplants for recurrent *C.difficile* infection throughout Centura's Colorado facilities. 2015.

Colorado Hospital Association's 2-Year Antimicrobial Stewardship Collaborative. 2015-2017.

Development and completion of the first Program Improvement/Quality Improvement (PI) education program at Swedish Hospital and throughout HCA facilities. Hospital based program to decrease *C.difficile* rates, recurrence, and severity. Swedish Medical Center, Englewood, CO. 2012-2013

Development of a joint Infectious Disease/Pathology teaching conference, Swedish Medical Center. 2012.

Metzger R, Swenson B, Bonatti H et al. Identification of Risk Factors for the Development of *Clostridium difficile*-Associated Diarrhea Following Treatment of Polymicrobial Surgical Infections. Ann Surg. 2010 Apr; 251(4): 722–727. (Acknowledgment)

DNA analysis of a C.difficile outbreak at a local community hospital, Augusta Health, Fisherville, VA 2008-2009

Ericsson CD, DuPont HL, Okhuysen PC, et al. Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med. 2007;14:312-9. (Acknowledgment for collecting field data)

Dupont H, Jiang Z, Okhuysen P, et al. A randomized, double blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812. (Acknowledgment for collecting field data)